• IMPALA Phase 3 Study of Molgradex Does Not Meet Primary Endpoint americanpharmaceuticalreview
    June 14, 2019
    Savara announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP ...
PharmaSources Customer Service